Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is a leader in the medical-surgical space, with a high percentage of domestic revenue and strong relationships with major US health systems. The company's large product offering, manufacturing capabilities, and logistics network give it significant scale and competitive advantages. Forward-thinking initiatives such as incorporating AI into its supply chain and expanding internationally position Medline for continued growth and success in the future.

Bears say

Medline is a leading provider of medical-surgical products and supply chain solutions in the US, with strong customer demand and increasing AI-driven efficiencies driving accelerated revenue growth. However, recent post-Q1 report pullback and near-term tariffs and margin pressure have created a buying opportunity. With strong brands and a dominant market position, along with its expanding digital control-tower platform and warehouse automation partnership, Medline is well-positioned for long-term growth and margin expansion. Despite currently trading at a premium valuation, the company's multiple growth levers and competitive advantages justify a Buy rating and target price.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.